ClinicalTrials.gg
CompletedNCT02224846Updated Sep 23, 2019Results posted

A Study of Tadalafil (LY450190) in Chinese Men With Erectile Dysfunction

A Phase 4 interventional study of Tadalafil in Erectile Dysfunction, sponsored by Eli Lilly and Company. Completed at 17 sites in China. Open to male participants aged 22 Years to 69 Years. Per ClinicalTrials.gov, last updated 2019-09-23.

Sponsored by Eli Lilly and Company · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
635
Allocation
Randomized
Ages
22 Years to 69 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 57 studies testing tadalafil in Erectile Dysfunction — 9 open to participants now, 9 under way, 3 of them phase 3. Tadalafil · Erectile Dysfunction.

Enrollment
7th of 56
635 · median 199
Started
2014
with 2 others
Phase 4
26 of 57
3 open now
Registered
33rd of 57
by date
Lead sponsor
26 of 57
Eli Lilly and Company

Among the 57 studies testing tadalafil in Erectile Dysfunction, this one is the 7th largest by enrollment of the 56 interventional ones that give a count, is one of 3 that started in 2014, is one of 26 in phase 4, and was the 33rd registered.

Erectile Dysfunction

702 studies on the registry are indexed under Erectile Dysfunction; 125 are open to participants now.

Browse Erectile Dysfunction studies →

Open to participants now

9 of the 57 studies testing tadalafil in Erectile Dysfunction are open now, in 4 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About tadalafil

Tadalafil: first FDA approval 2003 (CIALIS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 78 Erectile Dysfunction studies recruiting now, 31 (40%) set no upper age limit and 34 (44%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.

This study: 22 Years to 69 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies testing tadalafil in Erectile Dysfunction, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and effectiveness of the study drug, taken once daily, known as tadalafil in Chinese participants with erectile dysfunction (ED). The study will last about up to 25 months for each participant.

03

Conditions studied

  • Erectile Dysfunction

Browse trials for

04

Who can participate

Ages eligible
22 Years to 69 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a history of erectile dysfunction for at least 3 months.
  • Are sexually active and willing to remain sexually active with the same female partner during the study.
  • Are willing to have 4 or more attempts of sexual intercourse with female partner between screening and first treatment start day.
  • Are willing to stay away from any other medicines that the participants were already taking for erectile dysfunction during this study period.

Exclusion criteria

Exclusion Criteria:

  • Have erectile dysfunction, which is caused by any other primary sexual disorder.
  • Have certain problems with kidneys, liver, heart, blood sugar levels, eyes, or central nervous system (study doctor will discuss with participants).
  • Have a penis deformity or penile implant that in the opinion of the participants' doctor is significant.
  • Have (HIV) infection.
  • Are using certain kinds of medicines, which are not allowed in this study.
  • Are allergic to tadalafil.
  • Are planning to father a baby or are in a relationship with a pregnant partner.
  • Are participating or discontinued participation in the past 30 days from any another clinical trial, which is not compatible with this trial.
  • Have participated or discontinued from any other tadalafil clinical trial.
  • Have a history of drug, alcohol, or substance abuse within the past 6 months.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
635 participants (actual)

Study arms

  • Experimental
    2.5 mg/5 mg tadalafil

    2.5 mg tadalafil orally once daily for 3 months (Period 1) and then 5 mg tadalafil orally once daily for 21 months (Period 2).

    Drug: Tadalafil

  • Experimental
    5 mg tadalafil

    5 mg tadalafil orally once daily for 24 months (Period 1 and Period 2).

    Drug: Tadalafil

Interventions

  • Administered orally

    Also known as: LY450190

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Experiencing at Least One Treatment Emergent Adverse Event (Serious or Non-Serious)

    A Treatment Emergent Adverse Event (TEAE) was defined as an event that first occurs or worsens (increases in severity) after baseline, regardless of causality or severity. The percentage of participants with TEAEs was calculated by dividing the number of participants with at least 1 TEAE over the 12-Month treatment period by the total number of participants analyzed, multiplied by 100%. A summary of serious and other non-serious adverse events, regardless of causality, is located in the Reported Adverse Events module.

    Time frame: Baseline through Month 12

  2. Percentage of Participants Experiencing at Least One Adverse Event Leading to Discontinuation

    Data presented are the number of participants who experienced 1 or more AEs (all causalities and drug-related) and serious AEs (SAEs) that lead to discontinuation. A summary of serious and other non-serious adverse events, regardless of causality, is located in the Reported Adverse Events module.

    Time frame: Baseline through Month 12

Secondary outcomes

  1. Change From Baseline in the International Index of Erectile Function- Erectile Function (IIEF-EF) Domain Questionnaire Score

    IIEF- EF is the sum of Questions 1-5 and 15 of the IIEF. Questions 1-5 are scored 0 (no sexual activity for Question 1, no sexual stimulation for Question 2 and did not attempt intercourse for Questions 3-5) to 5 (high erectile function) and Question 15 is scored 1 (very low confidence) to 5 (very high confidence), for a total score ranging from 1 to 30. Higher scores represent better erectile function. Least Squares (LS) mean of the change from baseline is from Mixed effect Model Repeat Measurement (MMRM) model. The model included covariates baseline + visit + pooled investigator + baseline\*visit, where participant is a random effect.

    Time frame: Baseline, Month 1; Baseline, Month 3

  2. Change From Baseline in the IIEF-EF Domain Questionnaire Score of 5 mg Tadalafil Treatments

    IIEF- EF is the sum of Questions 1-5 and 15 of the IIEF. Questions 1-5 are scored 0 (no sexual activity for Question 1, no sexual stimulation for Question 2 and did not attempt intercourse for Questions 3-5) to 5 (high erectile function) and Question 15 is scored 1 (very low confidence) to 5 (very high confidence), for a total score ranging from 1 to 30. Higher scores represent better erectile function. Least Squares (LS) mean of the change from baseline is from Mixed effect Model Repeat Measurement (MMRM) model. The model included covariates baseline + visit + pooled investigator + baseline\*visit, where participant is a random effect.

    Time frame: Baseline, Month 6; Baseline, Month 12;Baseline, Month 18; Baseline, Month 24

  3. Percentage of Participants With "Yes" Responses to Sexual Encounter Profile (SEP) Diary

    Participant-assessed diary has 5 questions(QI-Q5): 4 of the 5 questions were analyzed. Q2: successful penetration, Q3: successful intercourse, Q4: satisfied with erection, and Q5: satisfied with sexual experience) for each sexual encounter made over a specified period of time. SEP Q1-Q5 scores were determined as the percentage of 'Yes' responses to each of the 5 questions out of all sexual attempts recorded during the time period.

    Time frame: Month 1, Month 3

  4. Percentage of Participants Achieving Normal Erectile Functioning

    Participants achieving a normal erectile functioning (defined as having an IIEF-EF Domain score of \>=26) at Month 1 and Month 3.

    Time frame: Month 1, Month 3

  5. Percentage of Participants Achieving Normal Erectile Functioning of 5 mg Tadalafil Treatments

    Participants achieving a normal erectile functioning (defined as having an IIEF-EF Domain score of \>=26) at Month 6 and Month 12.

    Time frame: Month 6, Month 12, Month 18, Month 24

  6. Percentage of Participants With "Yes" Responses to Global Assessment Questions (GAQ)1 and GAQ2

    Participants with "yes" responses to GAQ Question 1 (GAQ1) and GAQ Question 2 (GAQ2) of the GAQ questionnaire at Month 3 and Month 12. GAQ1: Has the treatment you have been taking during this study improved your erections? GAQ2: If yes, has the treatment improved your ability to engage in sexual activity?

    Time frame: Month 3, Month12, Month 24

07

Results

Posted Oct 27, 2017

Participant flow

Period 1 (Month 3)
Participant flow — Period 1 (Month 3)
Milestone2.5 mg/5 mg Tadalafil5 mg Tadalafil
Started211424
Received at least one dose of study drug210421
Completed192388
Not completed1936
Withdrew: Adverse event21
Withdrew: Lost to follow-up38
Withdrew: Protocol violation48
Withdrew: Withdrawal by subject818
Withdrew: Sponsor decision21
Period 2 (Month 3 to Month 12)
Participant flow — Period 2 (Month 3 to Month 12)
Milestone2.5 mg/5 mg Tadalafil5 mg Tadalafil
Started192388
Completed173357
Not completed1931
Withdrew: Adverse event12
Withdrew: Lost to follow-up35
Withdrew: Protocol violation03
Withdrew: Withdrawal by subject1519
Withdrew: Physician decision02
Period 2 (Month 12 to Month 24)
Participant flow — Period 2 (Month 12 to Month 24)
Milestone2.5 mg/5 mg Tadalafil5 mg Tadalafil
Started173357
Completed131283
Not completed4274
Withdrew: Adverse event34
Withdrew: Death10
Withdrew: Lost to follow-up713
Withdrew: Protocol violation411
Withdrew: Withdrawal by subject2543
Withdrew: Physician decision02
Withdrew: Sponsor decision21

Outcome measures

PrimaryPercentage of Participants Experiencing at Least One Treatment Emergent Adverse Event (Serious or Non-Serious)

A Treatment Emergent Adverse Event (TEAE) was defined as an event that first occurs or worsens (increases in severity) after baseline, regardless of causality or severity. The percentage of participants with TEAEs was calculated by dividing the number of participants with at least 1 TEAE over the 12-Month treatment period by the total number of participants analyzed, multiplied by 100%. A summary of serious and other non-serious adverse events, regardless of causality, is located in the Reported Adverse Events module.

Time frame:
Baseline through Month 12
Reported as:
Number · Percentage of participants
Percentage of Participants Experiencing at Least One Treatment Emergent Adverse Event (Serious or Non-Serious)
Percentage of participants2.5 mg/5 mg Tadalafil5 mg Tadalafil
Percentage of Participants Experiencing at Least One Treatment Emergent Adverse Event (Serious or Non-Serious)33.835.9
PrimaryPercentage of Participants Experiencing at Least One Adverse Event Leading to Discontinuation

Data presented are the number of participants who experienced 1 or more AEs (all causalities and drug-related) and serious AEs (SAEs) that lead to discontinuation. A summary of serious and other non-serious adverse events, regardless of causality, is located in the Reported Adverse Events module.

Time frame:
Baseline through Month 12
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing at Least One Adverse Event Leading to Discontinuation
percentage of participants2.5 mg/5 mg Tadalafil5 mg Tadalafil
Percentage of Participants Experiencing at Least One Adverse Event Leading to Discontinuation1.40.7
SecondaryChange From Baseline in the International Index of Erectile Function- Erectile Function (IIEF-EF) Domain Questionnaire Score

IIEF- EF is the sum of Questions 1-5 and 15 of the IIEF. Questions 1-5 are scored 0 (no sexual activity for Question 1, no sexual stimulation for Question 2 and did not attempt intercourse for Questions 3-5) to 5 (high erectile function) and Question 15 is scored 1 (very low confidence) to 5 (very high confidence), for a total score ranging from 1 to 30. Higher scores represent better erectile function. Least Squares (LS) mean of the change from baseline is from Mixed effect Model Repeat Measurement (MMRM) model. The model included covariates baseline + visit + pooled investigator + baseline\*visit, where participant is a random effect.

Time frame:
Baseline, Month 1; Baseline, Month 3
Reported as:
Least squares mean · units on a scale
Change From Baseline in the International Index of Erectile Function- Erectile Function (IIEF-EF) Domain Questionnaire Score
units on a scale2.5 mg/5 mg Tadalafil5 mg Tadalafil
Month 14.5 ± 0.426.2 ± 0.28
Month 36.1 ± 0.447.4 ± 0.28
SecondaryChange From Baseline in the IIEF-EF Domain Questionnaire Score of 5 mg Tadalafil Treatments

IIEF- EF is the sum of Questions 1-5 and 15 of the IIEF. Questions 1-5 are scored 0 (no sexual activity for Question 1, no sexual stimulation for Question 2 and did not attempt intercourse for Questions 3-5) to 5 (high erectile function) and Question 15 is scored 1 (very low confidence) to 5 (very high confidence), for a total score ranging from 1 to 30. Higher scores represent better erectile function. Least Squares (LS) mean of the change from baseline is from Mixed effect Model Repeat Measurement (MMRM) model. The model included covariates baseline + visit + pooled investigator + baseline\*visit, where participant is a random effect.

Time frame:
Baseline, Month 6; Baseline, Month 12;Baseline, Month 18; Baseline, Month 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in the IIEF-EF Domain Questionnaire Score of 5 mg Tadalafil Treatments
units on a scale2.5 mg/5 mg Tadalafil5 mg Tadalafil
Month 68.2 ± 0.387.9 ± 0.27
Month 128.1 ± 0.437.9 ± 0.27
Month 188.6 ± 0.398.3 ± 0.27
Month 248.6 ± 0.448.5 ± 0.28
SecondaryPercentage of Participants With "Yes" Responses to Sexual Encounter Profile (SEP) Diary

Participant-assessed diary has 5 questions(QI-Q5): 4 of the 5 questions were analyzed. Q2: successful penetration, Q3: successful intercourse, Q4: satisfied with erection, and Q5: satisfied with sexual experience) for each sexual encounter made over a specified period of time. SEP Q1-Q5 scores were determined as the percentage of 'Yes' responses to each of the 5 questions out of all sexual attempts recorded during the time period.

Time frame:
Month 1, Month 3
Reported as:
Mean · Percentage of participants
Percentage of Participants With "Yes" Responses to Sexual Encounter Profile (SEP) Diary
Percentage of participants2.5 mg/5 mg Tadalafil5 mg Tadalafil
Q2: successful penetration,Month 181.3 ± 34.5886.7 ± 27.58
Q2: successful penetration,Month 388.2 ± 28.5591.7 ± 23.11
Q3: successful intercourse,Month 141.2 ± 41.4849.5 ± 42.85
Q3: successful intercourse,Month 355.7 ± 43.1960.1 ± 42.39
Q4: satisfied with erection, Month 124.8 ± 35.6235.5 ± 41.63
Q4: satisfied with erection, Month 339.9 ± 43.7343.5 ± 43.46
Q5: satisfied with sexual experience,Month 120.4 ± 32.8131.1 ± 40.50
Q5: satisfied with sexual experience,Month 335.7 ± 41.9339.2 ± 43.06
SecondaryPercentage of Participants Achieving Normal Erectile Functioning

Participants achieving a normal erectile functioning (defined as having an IIEF-EF Domain score of \>=26) at Month 1 and Month 3.

Time frame:
Month 1, Month 3
Reported as:
Number · Percentage of partcipants
Percentage of Participants Achieving Normal Erectile Functioning
Percentage of partcipants2.5 mg/5 mg Tadalafil5 mg Tadalafil
Month 122.230.9
Month 331.637.6
SecondaryPercentage of Participants Achieving Normal Erectile Functioning of 5 mg Tadalafil Treatments

Participants achieving a normal erectile functioning (defined as having an IIEF-EF Domain score of \>=26) at Month 6 and Month 12.

Time frame:
Month 6, Month 12, Month 18, Month 24
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Normal Erectile Functioning of 5 mg Tadalafil Treatments
Percentage of participants2.5 mg/5 mg Tadalafil5 mg Tadalafil
Month 638.242.3
Month 1244.143.5
Month 1844.643.7
Month 2445.548.2
SecondaryPercentage of Participants With "Yes" Responses to Global Assessment Questions (GAQ)1 and GAQ2

Participants with "yes" responses to GAQ Question 1 (GAQ1) and GAQ Question 2 (GAQ2) of the GAQ questionnaire at Month 3 and Month 12. GAQ1: Has the treatment you have been taking during this study improved your erections? GAQ2: If yes, has the treatment improved your ability to engage in sexual activity?

Time frame:
Month 3, Month12, Month 24
Reported as:
Number · percentage of participants
Percentage of Participants With "Yes" Responses to Global Assessment Questions (GAQ)1 and GAQ2
percentage of participants2.5 mg/5 mg Tadalafil5 mg Tadalafil
Month 3: GAQ189.695.7
Month 12: GAQ196.697.5
Month 24: GAQ196.895.7
Month 3: GAQ286.592.1
Month 12: GAQ295.596.1
Month 24: GAQ296.294.5

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
2.5 mg/5 mg Tadalafil—15/210 (7.1%)86/210 (41%)
5 mg Tadalafil—17/421 (4%)178/421 (42.3%)
Most frequent serious events
Showing 10 of 34
Most frequent serious events
Event2.5 mg/5 mg Tadalafil5 mg Tadalafil
Large intestine polypGastrointestinal disorders2/2101/421
Diabetes mellitusMetabolism and nutrition disorders2/2100/421
Myocardial infarctionCardiac disorders1/2100/421
MaculopathyEye disorders1/2100/421
Duodenal ulcer haemorrhageGastrointestinal disorders1/2100/421
CholelithiasisHepatobiliary disorders1/2100/421
Hepatic cystHepatobiliary disorders1/2100/421
PneumoniaInfections and infestations1/2100/421
Urethral stricture postoperativeInjury, poisoning and procedural complications1/2100/421
Ankylosing spondylitisMusculoskeletal and connective tissue disorders1/2100/421
Most frequent other events
Showing 10 of 229
Most frequent other events
Event2.5 mg/5 mg Tadalafil5 mg Tadalafil
Viral upper respiratory tract infectionInfections and infestations18/21039/421
Upper respiratory tract infectionInfections and infestations5/21021/421
ProstatitisReproductive system and breast disorders7/2104/421
HeadacheNervous system disorders2/21013/421
PeriodontitisInfections and infestations6/2103/421
Alanine aminotransferase increasedInvestigations5/2101/421
DizzinessNervous system disorders3/2109/421
Abdominal pain upperGastrointestinal disorders4/2104/421
Chronic gastritisGastrointestinal disorders4/2103/421
Blood uric acid increasedInvestigations4/2101/421

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(years)2.5 mg/5 mg Tadalafil5 mg TadalafilTotal
Mean42.6 ± 11.1144.1 ± 10.9043.6 ± 10.98
Sex: Female, Male
Sex: Female, Male(Participants)2.5 mg/5 mg Tadalafil5 mg TadalafilTotal
Female000
Male211424635
Race (NIH/OMB)
Race (NIH/OMB)(Participants)2.5 mg/5 mg Tadalafil5 mg TadalafilTotal
American Indian or Alaska Native000
Asian211424635
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)2.5 mg/5 mg Tadalafil5 mg TadalafilTotal
China211424635
08

Study locations

17 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Beijing, 100020, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Changchun, 130021, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Changsha, 410011, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Chengdu, 610083, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Chongqing, 400037, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Fuzhou, 350001, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Guangzhou, 510180, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hangzhou, 310003, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hefei, 230022, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nanjing, 210008, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Qingdao, 266071, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Shanghai, 200092, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Suzhou City, 215004, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Wenzhou, 325035, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Wu Han, 430030, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Wuhan, 430022, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Yinchuan, 750004, China
09

References and documents

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2014, a primary completion of May 2016 and a completion of May 2017. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2017, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 20, 2014
First posted
Aug 25, 2014
Start
Oct 2014
Primary completionActual
May 2016
CompletionActual
May 2017
Results first posted
Oct 27, 2017
Last update
Sep 23, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02224846
Responsible party
Sponsor
First posted
Aug 25, 2014
Start date
Oct 2014
Primary completion
May 2016
Completion
May 2017
Results posted
Oct 27, 2017
Last update
Sep 23, 2019

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tadalafil

Start the discussion